Journal of the American Academy of Child & Adolescent Psychiatry
ARTICLESA Pilot Controlled Trial of Topiramate for Mania in Children and Adolescents With Bipolar Disorder
Section snippets
METHOD
This 4-week, prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group investigation was designed to enroll approximately 230 subjects. When topiramate monotherapy did not demonstrate superiority over placebo in acutely manic hospitalized adults with BPD (Powers et al., 2004), the trial was discontinued before enrollment was completed. This decision was made by the study sponsor in conjunction with an expert panel of advisors. The study was initially designed to
Subject Disposition and Baseline Characteristics
Of 77 children and adolescents screened, 56 were randomly assigned to treatment and were included in the efficacy and safety analyses (Fig. 1). Twenty-four (89%) and 21 (72%) subjects completed placebo and topiramate treatment, respectively (Fig. 1). One subject in the placebo group completed treatment but did not provide efficacy data for day 28, whereas one subject in the topiramate group discontinued treatment on day 26 but provided efficacy data for the final visit; thus, efficacy data were
DISCUSSION
The preliminary results of this study are inconclusive because of the early termination of the trial leading to only modest statistical power to detect between-group differences. The study originally was designed to treat 230 children and adolescents with topiramate or placebo for 28 days, but it was discontinued after only 56 subjects were enrolled because topiramate monotherapy did not demonstrate superiority over placebo in other trials of acutely manic hospitalized adults with BPD (Powers
REFERENCES (41)
- et al.
Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review
Clin Ther
(2002) - et al.
A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania
J Am Acad Child Adolesc Psychiatry
(2002) - et al.
Somatic treatment for depressive illnesses in children and adolescents
Psychiatr Clin North Am
(2004) - et al.
The Mania Rating Scale: can it be used in children? A preliminary report
J Am Acad Child Adolesc Psychiatry
(1992) - et al.
Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency
J Am Acad Child Adolesc Psychiatry
(1998) - et al.
Oral topiramate for treatment of alcohol dependence: a randomised controlled trial
Lancet
(2003) - et al.
Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data
J Am Acad Child Adolesc Psychiatry
(1997) - et al.
Validity of body mass index compared with other body-composition screening indexes for the assessment of body fatness in children and adolescents
Am J Clin Nutr
(2002) - et al.
Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders
Biol Psychiatry
(2002) - et al.
The Stanley Foundation Bipolar Treatment Outcome Network. II. Demographics and illness characteristics of the first 261 patients
J Affect Disord
(2001)
GABAergic dysfunction in mood disorders
Mol Psychiatry
A pilot study of topiramate as monotherapy in the treatment of acute mania
J Clin Psychopharmacol
Methodological issues and controversies in clinical trials with child and adolescent patients with bipolar disorder: report of a consensus conference
J Child Adolesc Psychopharmacol
Pharmacologic treatment of binge eating disorder
Int J Eat Disord
Topiramate as add-on treatment for patients with bipolar mania
Bipolar Disord
Adjunctive topiramate treatment for pediatric bipolar disorder: a retrospective chart review
J Child Adolesc Psychopharmacol
Rapid, continuous cycling and psychiatric co-morbidity in pediatric bipolar I disorder
Bipolar Disord
Phenomenology and longitudinal course of children with prepubertal and early adolescent bipolar disorder phenotype
Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design
J Clin Psychiatry
Cited by (127)
A systematic review and network meta-analysis on comparative efficacy, acceptability, and safety of treatments in acute bipolar mania in youths
2024, Journal of Affective DisordersToward prevention of bipolar disorder in at-risk children: Potential strategies ahead of the data
2020, Journal of Affective DisordersCitation Excerpt :Adjunctive N-Acetylcysteine is effective in adults with bipolar disorder and alcohol, substance abuse or marijuana use (Berk et al., 2013), with or without a comorbid diagnosis of PTSD (Back et al., 2016). Adjunctive topiramate is effective against alcohol and cocaine use in adults, although its efficacy in youth is unclear (Delbello et al., 2005). The effectiveness and safety outcomes of these studies in at risk and prodromal children could be evaluated with a wide array of study designs, sequentially ranging in methodological rigor from (1) case control studies of individual children with and without high-risk syndromes who have detailed longitudinal ratings; (2) open clinical case series, preferably with comparisons with historical data; and (3) later randomized open “practical” comparative trials (Geddes et al., 2010; March et al., 2010).
Pediatric Bipolar Disorder
2018, Complex Disorders in Pediatric Psychiatry: A Clinician's GuideEarly pharmacological interventions in youth
2018, Bipolar Disorder Vulnerability: Perspectives from Pediatric and High-Risk PopulationsPsychopharmacology of Bipolar Disorders in Children and Adolescents
2017, Pediatric Clinics of North America
Presented in part at the American College of Neuropsychopharmacology 42nd Annual Meeting, San Juan, PR, December 8, 2003.
This study was supported by a grant from Johnson & Johnson Pharmaceutical Research & Development, LLC. The authors thank Robert Kowatch for standardizing raters for psychometric testing, Li-Joy Wang for assistance with statistical analyses, Jonathan Latham for assistance in preparing the manuscript, and Alan Unis for assistance with protocol development. The authors acknowledge contributions from the following study consultants and investigators: Valerie Arnold, Memphis; Charles Bailey, Orlando, FL; Mark Bangs, Indianapolis; Jeffrey Blumer, Cleveland; Sharon Cain, Kansas City, KS; Gabrielle Carlson, Stony Brook, NY; Kiki Chang, Stanford, CA; Joseph Haraszti, Cerritos, CA; Arnold Hartman, West Palm Beach, FL; Willis Holloway, Oklahoma City; Alan Jacobson, Hollywood, FL; Vivian Kafantaris, Glen Oaks, NY; Alain Katic, Bellaire, TX; Arifula Khan, Bellevue, WA; Robert Kowatch, Cincinnati; Adam Lowy, Washington, DC; Morteza Marandi, Cerritos, CA; William Murphy, Overland Park, KS; Steven Pliszka, San Antonio, TX; Michael Plopper, San Diego; Sohail Punjwani, North Miami, FL; Joachim Raese, Riverside, CA; Adelaide Robb, Washington, DC; David Sack, Cerritos, CA; Russell Scheffer, Dallas; Scott Segal, North Miami, FL; J. Stone, Austin, TX; Tram Tran-Johnson, San Diego; Himanshu Upadhyaya, Charleston, SC; Amit Vijapura, Jacksonville, FL; Karen Wagner, Galveston, TX; Elizabeth Weller, Merion Station, PA; Craig Wronski, Pico Rivera, CA; Kashinath Yadalam, Lake Charles, LA.
Disclosure: Dr. DelBello has received research support, speaker honoraria, and/or consulting fees from Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Ortho-McNeil, Pfizer, and Shire. Dr. Findling has received research support, speaker honoraria, and/or consulting fees from Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Celltech-Medeva, Forest, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, New River, Novartis, Otsuka, Pfizer, Shire, Solvay, and Wyeth. Drs. Kushner, Wang, Olson, and Rosenthal and Ms. Capece are currently employees of Ortho-McNeil Pharmaceutical Inc. Dr. Fazzio is a former employee of Ortho-McNeil Pharmaceutical Inc.